{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T02:12:31Z","timestamp":1713406351637},"reference-count":55,"publisher":"Spandidos Publications","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomed Rep"],"DOI":"10.3892\/br.2024.1772","type":"journal-article","created":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T08:25:30Z","timestamp":1711700730000},"source":"Crossref","is-referenced-by-count":0,"title":["Effects of abrocitinib on pruritus and eczema symptoms and tolerance in patients with moderate\u2011to\u2011severe atopic dermatitis in randomized, double\u2011blind and placebo\u2011controlled trials: A systematic review and a meta\u2011analysis"],"prefix":"10.3892","volume":"20","author":[{"given":"Xingxing","family":"Xie","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Yaan People's Hospital, Yaan, Sichuan 625000, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Nanbu People's Hospital, Nanchong, Sichuan 637300, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fujing","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Yaan People's Hospital, Yaan, Sichuan 625000, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Fan","sequence":"additional","affiliation":[{"name":"Clinical Trial Center for Drugs and Medical Devices, Yaan People's Hospital, Yaan, Sichuan 625000, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2024,3,29]]},"reference":[{"issue":"2721","key":"key20240417113108_b1-BR-20-5-01772","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13172721","article-title":"Ultra-high frequency ultrasound (UHFUS) assessment of barrier function in moderate-to-severe atopic dermatitis during dupilumab treatment","volume":"13","author":"Dini","year":"2023","journal-title":"Diagnostics (Basel)"},{"key":"key20240417113108_b2-BR-20-5-01772","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.anai.2018.07.006","article-title":"Patient burden and quality of life in atopic dermatitis in US adults: A population-based cross-sectional study","volume":"121","author":"Silverberg","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"key20240417113108_b3-BR-20-5-01772","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s13555-021-00488-x","article-title":"extent and impact of inadequate disease control in US adults with a history of moderate to severe atopic dermatitis following introduction of new treatments","volume":"11","author":"Vilsb\u00f8ll","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"14","key":"key20240417113108_b4-BR-20-5-01772","doi-asserted-by":"publisher","DOI":"10.1186\/s41232-017-0044-7","article-title":"The etiopathogenesis of atopic dermatitis: Barrier disruption, immunological derangement, and pruritus","volume":"37","author":"Rerknimitr","year":"2017","journal-title":"Infamm Regen"},{"key":"key20240417113108_b5-BR-20-5-01772","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/s0091-6749(99)70536-1","article-title":"Worldwide variations in the prevalence of symptoms of atopic eczema in the international study of asthma and allergies in childhood","volume":"103","author":"Williams","year":"1999","journal-title":"J Allergy Clin Immunol"},{"key":"key20240417113108_b6-BR-20-5-01772","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/j.jaci.2009.10.009","article-title":"Global variations in prevalence of eczema symptoms in children from ISAAC phase three","volume":"124","author":"Odhiambo","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"key20240417113108_b7-BR-20-5-01772","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1080\/08923973.2021.1889583","article-title":"Atopic dermatitis: New insight into the etiology, pathogenesis, diagnosis and novel treatment strategies","volume":"43","author":"Mandlik","year":"2021","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"key20240417113108_b8-BR-20-5-01772","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1080\/1744666X.2021.1940962","article-title":"The IL-4, IL-13 and IL-31 pathways in atopic dermatitis","volume":"17","author":"Dubin","year":"2021","journal-title":"Expert Rev Clin Immunol"},{"key":"key20240417113108_b9-BR-20-5-01772","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.jaci.2022.12.002","article-title":"Comorbidities of atopic dermatitis-what does the evidence say?","volume":"151","author":"Thyssen","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"key20240417113108_b10-BR-20-5-01772","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/S0140-6736(15)00149-X","article-title":"Atopic dermatitis","volume":"387","author":"Weidinger","year":"2016","journal-title":"Lancet"},{"key":"key20240417113108_b11-BR-20-5-01772","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1111\/cea.14301","article-title":"Non-biologic systemic treatments for atopic dermatitis: Current state of the art and future directions","volume":"53","author":"Paolino","year":"2023","journal-title":"Clin Exp Allergy"},{"key":"key20240417113108_b12-BR-20-5-01772","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1001\/jamadermatol.2022.0455","article-title":"Systemic immunomodulatory treatments for atopic Dermatitis: Update of a living systematic review and network meta-analysis","volume":"158","author":"Drucker","year":"2022","journal-title":"JAMA Dermatol"},{"key":"key20240417113108_b13-BR-20-5-01772","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1001\/jamadermatol.2021.3023","article-title":"Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: A randomized clinical trial","volume":"157","author":"Blauvelt","year":"2021","journal-title":"JAMA Dermatol"},{"key":"key20240417113108_b14-BR-20-5-01772","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1007\/s13555-021-00534-8","article-title":"Itch and sleep improvements with baricitinib in patients with atopic dermatitis: A post hoc analysis of 3 phase 3 studies","volume":"11","author":"Buhl","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"AB171","key":"key20240417113108_b15-BR-20-5-01772","article-title":"28032 Rapid itch improvement with upadacitinib with or without concomitant topical corticosteroids (TCS) in moderate-to-severe atopic dermatitis (AD): Results from 3 phase 3 studies (Measure Up1, Measure Up 2, and AD Up)","volume":"85","author":"Blauvelt","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"key20240417113108_b16-BR-20-5-01772","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1016\/j.jaad.2020.02.060","article-title":"Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: Analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS","volume":"82","author":"Silverberg","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"S61","key":"key20240417113108_b17-BR-20-5-01772","article-title":"Rapid and sustained improvements in itch and sleep with tralokinumab treatment in patients with moderate-to-severe Atopic Dermatitis, a post hoc analysis of pooled data from ECZTRA 1 and 2","volume":"5","author":"Simpson","year":"2021","journal-title":"SKIN J Cutan Med"},{"key":"key20240417113108_b18-BR-20-5-01772","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1111\/jdv.19280","article-title":"Abrocitinib efficacy and safety in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND study","volume":"37","author":"Reich","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"key20240417113108_b19-BR-20-5-01772","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s40257-023-00785-5","article-title":"Efficacy and safety of abrocitinib in patients with severe and\/or difficult-to-treat atopic dermatitis: A post hoc analysis of the randomized phase 3 JADE COMPARE trial","volume":"24","author":"Simpson","year":"2023","journal-title":"Am J Clin Dermatol"},{"issue":"e059979","key":"key20240417113108_b20-BR-20-5-01772","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-059979","article-title":"Oral Janus kinase inhibitors and venous thromboembolic events in atopic dermatitis: Protocols for a case-time control study and a nested case-control study based on the French national health insurance (SNDS) cohort","volume":"12","author":"Berthe","year":"2022","journal-title":"BMJ Open"},{"key":"key20240417113108_b21-BR-20-5-01772","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/j.jaad.2023.05.077","article-title":"An observational study of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab","volume":"89","author":"Tong","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"key20240417113108_b22-BR-20-5-01772","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): A 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"key":"key20240417113108_b23-BR-20-5-01772","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s40265-017-0701-9","article-title":"JAK-STAT signaling as a target for inflammatory and autoimmune diseases: Current and future prospects","volume":"77","author":"Banerjee","year":"2017","journal-title":"Drugs"},{"key":"key20240417113108_b24-BR-20-5-01772","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jaad.2021.05.075","article-title":"Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 atopic dermatitis efficacy and safety (JADE) REGIMEN phase 3 trial","volume":"86","author":"Blauvelt","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"key20240417113108_b25-BR-20-5-01772","doi-asserted-by":"publisher","first-page":"ii24","DOI":"10.1093\/rheumatology\/keaa895","article-title":"The safety of JAK-1 inhibitors","volume":"60 (Suppl 2)","author":"Clarke","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"key20240417113108_b26-BR-20-5-01772","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s41669-023-00459-2","article-title":"Cost-effectiveness analysis of abrocitinib compared with other systemic treatments for severe atopic dermatitis in spain","volume":"8","author":"Romero Jim\u00e9nez","year":"2024","journal-title":"Pharmacoecon Open"},{"key":"key20240417113108_b27-BR-20-5-01772","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/LEXB9006","article-title":"Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis","volume":"28","author":"Edwards","year":"2024","journal-title":"Health Technol Assess"},{"issue":"1419","key":"key20240417113108_b28-BR-20-5-01772","doi-asserted-by":"publisher","DOI":"10.3390\/life13061419","article-title":"Atopic dermatitis: Disease features, therapeutic options, and a multidisciplinary approach","volume":"13","author":"Lugovi\u0107-Mihi\u0107","year":"2023","journal-title":"Life (Basel)"},{"issue":"e3280","key":"key20240417113108_b29-BR-20-5-01772","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3280","article-title":"Guidelines on the diagnosis and treatment of foot infection in persons with diabetes (IWGDF 2019 update)","volume":"36 (Suppl 1)","author":"Lipsky","year":"2020","journal-title":"Diabetes Metab Res Rev"},{"key":"key20240417113108_b30-BR-20-5-01772","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1046\/j.1365-2133.2001.04379.x","article-title":"Evaluation of diagnostic criteria for atopic dermatitis","volume":"33","author":"Gu","year":"2000","journal-title":"Chin J Dermatology"},{"key":"key20240417113108_b31-BR-20-5-01772","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3109\/09546634.2013.865009","article-title":"The 5-point investigator's global assessment (IGA) scale: A modified tool for evaluating plaque psoriasis severity in clinical trials","volume":"26","author":"Langley","year":"2015","journal-title":"J Dermatolog Treat"},{"key":"key20240417113108_b32-BR-20-5-01772","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/DER.0000000000000895","article-title":"The eczema area and severity index-a practical guide","volume":"33","author":"Hanifin","year":"2022","journal-title":"Dermatitis"},{"key":"key20240417113108_b33-BR-20-5-01772","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s40261-023-01336-w","article-title":"Comparison of long-term effectiveness and safety of upadacitinib for atopic dermatitis between dupilumab-exposed and dupilumab-na\u00efve patients","volume":"44","author":"Napolitano","year":"2024","journal-title":"Clin Drug Investig"},{"issue":"b2700","key":"key20240417113108_b34-BR-20-5-01772","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"key20240417113108_b35-BR-20-5-01772","doi-asserted-by":"publisher","first-page":"e320","DOI":"10.1097\/PTS.0000000000000768","article-title":"Implementing high-reliability organization principles into practice: A rapid evidence review","volume":"18","author":"Veazie","year":"2022","journal-title":"J Patient Saf"},{"key":"key20240417113108_b36-BR-20-5-01772","author":"Higgins"},{"issue":"25","key":"key20240417113108_b37-BR-20-5-01772","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6963-5-25","article-title":"Systems for grading the quality of evidence and the strength of recommendations II: Pilot study of a new system","volume":"5","author":"Atkins","year":"2005","journal-title":"BMC Health Serv Res"},{"issue":"ED000142","key":"key20240417113108_b38-BR-20-5-01772","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.ED000142","article-title":"Updated guidance for trusted systematic reviews: A new edition of the cochrane handbook for systematic reviews of interventions","volume":"10","author":"Cumpston","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"key20240417113108_b39-BR-20-5-01772","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1097\/01.BRS.0000065484.95996.AF","article-title":"Updated method guidelines for systematic reviews in the cochrane collaboration back review group","volume":"28","author":"van Tulder","year":"2003","journal-title":"Spine (Phila Pa 1976)"},{"key":"key20240417113108_b40-BR-20-5-01772","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1056\/NEJMoa2019380","article-title":"Abrocitinib versus placebo or dupilumab for atopic dermatitis","volume":"384","author":"Bieber","year":"2021","journal-title":"N Engl J Med"},{"key":"key20240417113108_b41-BR-20-5-01772","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1001\/jamadermatol.2021.2830","article-title":"Efficacy and safety of abrocitinib in combination with topical therapy in adolescents with moderate-to-severe atopic dermatitis: The JADE TEEN randomized clinical trial","volume":"157","author":"Eichenfield","year":"2021","journal-title":"JAMA Dermatol"},{"key":"key20240417113108_b42-BR-20-5-01772","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1001\/jamadermatol.2019.2855","article-title":"Efficacy and safety of oral Janus kinase 1 inhibitor abrocitinib for patients with atopic dermatitis: A phase 2 randomized clinical trial","volume":"155","author":"Gooderham","year":"2019","journal-title":"JAMA Dermatol"},{"key":"key20240417113108_b43-BR-20-5-01772","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1001\/jamadermatol.2020.1406","article-title":"Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: A randomized clinical trial","volume":"156","author":"Silverberg","year":"2020","journal-title":"JAMA Dermatol"},{"key":"key20240417113108_b44-BR-20-5-01772","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(20)30732-7","article-title":"Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): A multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"396","author":"Simpson","year":"2020","journal-title":"Lancet"},{"issue":"d5928","key":"key20240417113108_b45-BR-20-5-01772","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","article-title":", et al: The cochrane collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"key20240417113108_b46-BR-20-5-01772","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.anai.2017.10.039","article-title":"Atopic dermatitis yardstick: Practical recommendations for an evolving therapeutic landscape","volume":"120","author":"Boguniewicz","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"key20240417113108_b47-BR-20-5-01772","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/S0140-6736(22)01199-0","article-title":"Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: A randomised, double-blind, multicentre phase 3 trial","volume":"400","author":"Reich","year":"2022","journal-title":"Lancet"},{"key":"key20240417113108_b48-BR-20-5-01772","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1080\/09546634.2020.1832185","article-title":"Quantifying patient preferences for systemic atopic dermatitis treatments using a discrete-choice experiment","volume":"33","author":"Boeri","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"key20240417113108_b49-BR-20-5-01772","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1080\/09546634.2021.1898530","article-title":"The current treatment landscape in adult atopic dermatitis in the United States: Results from a cross-sectional real-world study","volume":"33","author":"Boytsov","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"key20240417113108_b50-BR-20-5-01772","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1136\/bmj.323.7304.101","article-title":"Systematic reviews in health care: Investigating and dealing with publication and other biases in meta-analysis","volume":"323","author":"Sterne","year":"2001","journal-title":"BMJ"},{"issue":"2342","key":"key20240417113108_b51-BR-20-5-01772","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02342","article-title":"Targeting the Janus kinase family in autoimmune skin diseases","volume":"10","author":"Howell","year":"2019","journal-title":"Front Immunol"},{"issue":"4130","key":"key20240417113108_b52-BR-20-5-01772","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22084130","article-title":"Molecular mecha-nisms of atopic dermatitis pathogenesis","volume":"22","author":"Sroka-Tomaszewska","year":"2021","journal-title":"Int J Mol Sci"},{"key":"key20240417113108_b53-BR-20-5-01772","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1007\/s13555-023-00948-6","article-title":"Abrocitinib 100 mg once daily for moderate-to-severe atopic dermatitis: A review of efficacy and safety, and expert opinion on use in clinical practice","volume":"13","author":"Gooderham","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"key20240417113108_b54-BR-20-5-01772","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s40257-021-00618-3","article-title":"Integrated safety analysis of abrocitinib for the treatment of moderate-to-severe atopic dermatitis from the phase II and phase III clinical trial program","volume":"22","author":"Simpson","year":"2021","journal-title":"Am J Clin Dermatol"},{"issue":"2061","key":"key20240417113108_b55-BR-20-5-01772","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02061","article-title":"The dual nature of type I and type II interferons","volume":"9","author":"Lee","year":"2018","journal-title":"Front Immunol"}],"container-title":["Biomedical Reports"],"original-title":[],"deposited":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T09:14:39Z","timestamp":1713345279000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/br.2024.1772"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,29]]},"references-count":55,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,3,29]]}},"URL":"https:\/\/doi.org\/10.3892\/br.2024.1772","relation":{},"ISSN":["2049-9434","2049-9442"],"issn-type":[{"value":"2049-9434","type":"print"},{"value":"2049-9442","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,29]]},"article-number":"84"}}